Medical Care Technologies Inc. Launches AI Platform for Early Basal Cell Carcinoma Detection
Medical Care Technologies (OTC:MDCE) has launched an innovative AI platform designed for early detection of basal cell carcinoma (BCC), the most common type of skin cancer. The platform enables at-home screening and monitoring through advanced texture and reflectance analysis technology.
The AI system features sophisticated capabilities including pearly nodule identification, vascular pattern recognition, ulceration tracking, and pixel-level texture classification to distinguish between benign growths and potential carcinomas. This technology aims to address the limited access to dermatology services by providing accessible, non-invasive screening solutions.
Medical Care Technologies (OTC:MDCE) ha lanciato una piattaforma IA innovativa per l’individuazione precoce del carcinoma basocellulare (BCC), il tipo più comune di cancro della pelle. La piattaforma permette screening e monitoraggio a domicilio tramite avanzate tecniche di analisi della texture e della riflettanza.
Il sistema AI offre capacità complesse tra cui identificazione di noduli lucidi, riconoscimento di pattern vascolari, monitoraggio di ulcerazioni e classificazione di texture a livello di pixel per distinguere tra lesioni benigne e potenziali carcinomi. Questa tecnologia mira a superare la limitata accessibilità ai servizi dermatologici fornendo soluzioni di screening non invasive e accessibili.
Medical Care Technologies (OTC:MDCE) ha lanzado una innovadora plataforma de IA diseñada para la detección temprana del carcinoma basocelular (BCC), el tipo de cáncer de piel más común. La plataforma permite cribado y monitoreo en casa mediante tecnología avanzada de análisis de textura y reflectancia.
El sistema de IA cuenta con capacidades sofisticadas como identificación de nódulos perlados, reconocimiento de patrones vasculares, seguimiento de ulceraciones y clasificación de texturas a nivel de píxel para distinguir entre crecimientos benignos y posibles carcinomas. Esta tecnología busca abordar el limitado acceso a los servicios dermatológicos al proporcionar soluciones de cribado no invasivas y accesibles.
MDCE는 피부암 중 가장 흔한 유형인 기저세포암(BCC)을 조기에 감지하기 위한 혁신적인 AI 플랫폼을 선보였습니다. 이 플랫폼은 고도화된 질감 및 반사율 분석 기술을 통해 가정에서의 선별 및 모니터링이 가능하도록 합니다.
이 AI 시스템은 진주같은 결절 식별, 혈관 패턴 인식, 궤양 추적, 픽셀 수준의 질감 분류 등 정교한 기능을 갖추고 있어 양성 성장과 잠재적 암종을 구분합니다. 이 기술은 비침습적이고 접근 가능한 선별 솔루션을 제공해 피부과 진료 접근성을 높이고자 합니다.
Medical Care Technologies (OTC:MDCE) a lancé une plateforme IA innovante conçue pour la détection précoce du carcinome basocellulaire (BCC), le type de cancer de la peau le plus courant. La plateforme permet un diagnostic et un suivi à domicile grâce à une technologie avancée d’analyse de texture et de réflectance.
Le système IA possède des capacités sophistiquées telles que l’identification de nodules perlés, la reconnaissance de motifs vasculaires, le suivi des ulcérations et la classification de textures au niveau des pixels pour distinguer les lésions bénignes des carcinomes potentiels. Cette technologie vise à pallier le manque d’accès aux services dermatologiques en offrant des solutions de dépistage non invasives et accessibles.
Medical Care Technologies (OTC:MDCE) hat eine innovative KI-Plattform zur frühzeitigen Erkennung des Basalzellkarzinoms (BCC) entwickelt, der häufigsten Form von Hautkrebs. Die Plattform ermöglicht Screening und Monitoring zu Hause durch fortschrittliche Textur- und Reflektanzanalyse-Technologie.
Das KI-System bietet anspruchsvolle Funktionen wie Perlknötchen-Erkennung, Erkennung von Gefäßmustern, Ulzerationsverfolgung und Pixel-Genauigkeits-Texturklassifizierung, um zwischen gutartigen Wachstum und potenziellen Karzinomen zu unterscheiden. Diese Technologie zielt darauf ab, den begrenzten Zugang zu dermatologischen Diensten durch zugängliche, nicht-invasive Screening-Lösungen zu verbessern.
Medical Care Technologies (OTC:MDCE) أطلقت منصة ذكاء اصطناعي مبتكرة مصممة للكشف المبكر عن سرطان الخلايا القاعدية (BCC)، وهو النوع الأكثر شيوعاً من سرطان الجلد. تتيح المنصة الفحص والمراقبة في المنزل من خلال تكنولوجيا تحليل النسيج والانعكاس المتقدمة.
يتميز نظام الذكاء الاصطناعي بقدرات متقدمة بما في ذلك تحديد العقد القُرانية اللامعة، والتعرّف على نمط الأوعية الدقيقة، وتتبع التقرحات، وتصنيف النسيج على مستوى البكسل للتمييز بين النموّ الحميد والسرطانات المحتملة. تهدف هذه التقنية إلى معالجة محدودية الوصول إلى خدمات الجلدية من خلال توفير حلول فحص غير جراحية وسهلة الوصول.
Medical Care Technologies (OTC:MDCE) 已推出一款创新的人工智能平台，旨在早期检测基底细胞癌（BCC），这是最常见的皮肤癌类型。该平台通过先进的纹理与反射分析技术实现<居家筛查与监测
AI 系统具备包括珍珠样结节识别、血管模式识别、溃疡追踪、像素级纹理分类等复杂功能，用以区分良性生长与潜在癌变。该技术旨在通过提供易于获取的非侵入性筛查方案，改善皮肤科服务的可及性。
- Introduction of innovative AI platform for early skin cancer detection
- Technology enables non-invasive, at-home screening accessibility
- System provides continuous monitoring and early warning capabilities
- Addresses significant market need with millions of annual BCC cases
- Early-stage technology without proven clinical validation
- Operating in highly regulated medical device market
- Potential competition from established medical device companies
MESA, ARIZONA / ACCESS Newswire / September 19, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a pioneer in AI-powered diagnostics, today unveiled its breakthrough artificial intelligence platform for the detection and monitoring of basal cell carcinoma (BCC), the most common form of skin cancer.
Though rarely fatal, untreated BCC can cause severe disfigurement, local tissue invasion, and costly surgeries. Current detection methods rely heavily on dermatology access, which remains limited for many populations. MDCE's AI platform addresses this gap by enabling scalable, non-invasive, and at-home screening.
Technical Innovation
MDCE's AI system applies texture and reflectance analysis, recognizing hallmark features of BCC including:
Pearly or translucent nodule identification
Subsurface vascular pattern recognition (telangiectasia)
Ulceration tracking over time
Distinguishing BCC from benign growths through pixel-level texture classification
With continuous longitudinal monitoring, the system can differentiate between harmless lesions and early-stage carcinomas, providing critical alerts for medical follow-up.
"BCC affects millions each year, yet many cases go undiagnosed until they cause permanent damage," said Marshall Perkins, CEO of MDCE. "Our AI tool can help change that equation by bringing early detection directly into the patient's hands."
About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTC: MDCE) develops AI-based solutions for preventive medicine, with a focus on dermatology, neurology, and ocular health.
Company Websites: www.medicalcaretechnologies.com | www.mdcestock.com
Forward-Looking Statements: This press release contains forward-looking statements within the meaning of federal securities laws. Actual results may differ materially.
Contact:
Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com
SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)
View the original press release on ACCESS Newswire
FAQ
What is Medical Care Technologies' (MDCE) new AI platform designed to detect?
How does MDCE's AI platform detect basal cell carcinoma?
What problem is MDCE's new AI platform solving?
Who is the CEO of Medical Care Technologies (MDCE)?
What are the key features of MDCE's AI skin cancer detection system?
